Skip to content

Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies

Understanding Impaired Concentration, Attentional Deficits and Their Pathophysiology in Postural Orthostatic Tachycardia Syndrome (POTS) and Other Autonomic Neuropathies (POTSKog-Study Aachen)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03681080
Acronym
POTSKog
Enrollment
110
Registered
2018-09-21
Start date
2017-04-01
Completion date
2023-05-30
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Failure, Cognitive Impairment, Dysautonomia, Ehlers-Danlos Syndrome, Postural Tachycardia Syndrome, Pure Autonomic Failure

Brief summary

People with POTS, autoimmune autonomic neuropathy (AAN), pure autonomic failure (PAF), SFN and Ehlers Danlos Syndrome (EDS) do not only suffer from orthostatic symptoms such as dizziness, headache, neck pain, blurred vision or (pre-) syncope. They also experience deficits in attention and concentration (more precisely deficits in selective perspective, operating speed, executive functions and memory performance) mainly in upright position. Only few studies concerning cognitive impairment in autonomic neuropathies, their frequency, aetiology and therapy exist. Many patients concerned, especially with POTS, report attention deficits and brain fog with problems in their everyday life and work, predominantly in upright posture. Specific symptomatic or medical therapies do not exist. Medical treatment with Modafinil is discussed and part of a current study at Vanderbilt Autonomic Dysfunction Centre (1-5). The investigators want to investigate if problems of concentration, attention and/or cognitive dysfunction exist in people with POTS, AAN, SFN and EDS compared to healthy controls (HC). Thus the investigators use detailed clinical, autonomic and neuropsychological tests in different body positions (lying, sitting and standing) as also acute therapy (leg crossing).

Detailed description

We are still recruting healthy controls and patients with autoimmune autonomic neuropathy in order to perform titl table examination and laboratory testing on day one, ono an empty stomach, without morning medication. Cognitive testing is performed on day two after randomization in three groups: lying, standing and standing with legs crossed.

Interventions

PROCEDUREleg crossing

As Counter maneuvre legs will be crossed and cognitive tests will be performed.

Sponsors

RWTH Aachen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* AAN, SFN, hEDS, POTS or healthy control * diagnosis in our clinic on the basis of anamnesis, clinical data as neurological examination, tilt table, QST, skin biopsy, norepinephrine values, vitamine B12, antibodies

Exclusion criteria

for all participants * pregnancy, nonage,severe heart insufficiency, deep brain Stimulation, pace maker, drug consumption, large fibre polyneuropathy for controls * medication influencing blood pressure, psychiatric disease, synkopes or dizziness, neurological disorders esp. polyneuropathy, dementia, vitamine or iron deficiency

Design outcomes

Primary

MeasureTime frameDescription
cognitive function: Stroop, TMT A und Bduring intervention (Leg crossing)Change of results of cognitive function tests lying compared to standing and leg crossing

Secondary

MeasureTime frameDescription
blood pressure Change (mmHg)during intervention (Leg crossing)Change between blood pressure lying compared to compared to standing and leg crossing
Heart frequency Change (B/min)during intervention (Leg crossing)Change between heart frequency lying compared to compared to standing and leg crossing
cerebral blood flow velocityduring intervention (Leg crossing)Change between cerebral blood flow compared to compared to standing and leg crossing

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026